Company Overview

Key Financial Performance Figures (FY 2025-26)

  • Revenue from Operations: ₹827.9 crore (18.9% YoY growth from ₹696.0 crore in FY25) / ₹8,023.65 million (18.1% growth)
  • EBITDA: ₹294.1 crore (12.8% YoY growth)
  • EBITDA Margin: 35.5%
  • Profit After Tax: ₹209.1 crore (11.2% YoY growth) / ₹2,091.20 million (11.3% growth)
  • PAT Margin: 25.26%
  • Earnings Per Share: ₹25.98 (vs ₹23.35 in FY25)
  • Dividend Recommended: Final dividend of ₹1.00 per equity share (50% on face value of ₹2) totaling ₹80.48 million
  • Capital Expenditure: ₹152 crore directed towards Ambernath facility and expansion projects
  • Total Assets: ₹13,571.07 million (FY25: ₹11,173.47 million)
  • Total Equity: ₹11,977.33 million (FY25: ₹9,967.60 million)

Operational Highlights

  • Backward Integration: 76% of revenue came from backward-integrated products
  • Export Contribution: 82% of total revenue (₹7,261.83 million)
  • Geographic Presence: Operations in 120+ countries with over 1,500 customers
  • Product Portfolio: 40+ APIs across therapeutic segments including anaesthetics, antihistamines, analgesics, vitamins, anti-asthmatics, and anti-allergics
  • Manufacturing Capacity: 1,050 KL reactor capacity across 5 manufacturing blocks
  • Employee Strength: 607 employees as of March 31, 2026

Regulatory and Compliance Matters

  • USFDA Inspection: Successful unannounced inspection at Lote facility in February 2026 with one minor observation
  • Certifications: USFDA, Health Canada, WHO-GMP, ISO 9001:2015, EDQM, FSSAI, Halal certifications
  • Regulatory Filings: 21 US DMFs, 11 CEPs, 10 CADIFA (Brazil), 5 KDMF (Korea), 4 NMPA (China), 50+ ROW registrations
  • Auditor Opinion: Kakaria & Associates issued unqualified opinion confirming adequate internal financial controls and compliance with Companies Act 2013
  • Disputed Dues: ₹8.22 million under litigation (₹6.55 million Service Tax, ₹1.67 million MEIS)

Strategic Developments

  • CMO/CDMO Business: One project entered commercial phase with committed volumes for next decade
  • New Product Launches: Commercialized Lisdexamfetamine Dimesylate, Ibuprofen Picanol, Sevoflurane, and ATS-8
  • R&D Investment: Three R&D centers with 90 scientists; filed patents for Lisdexamfetamine and Ibuprofen Picanol processes
  • Capacity Expansion: Commissioned Module E production block at Lote, increasing capacity from 597 KLPD to 932 KLPD
  • New Facilities: Commercialized CMO facility at Ambernath; received clearances for Patalganga site development

Dividend and AGM Information

  • Record Date: September 4, 2026 for final dividend entitlement
  • Payment Date: On or after September 24, 2026, subject to approval at AGM
  • Dividend Amount: ₹80.48 million total outflow if approved
  • AGM Date: September 24, 2026 at 3:00 PM IST via Video Conferencing
  • AGM Business: Adoption of financial statements, dividend declaration, director appointments, ratification of cost auditor remuneration

Corporate Governance and CSR

  • Board Composition: 10 directors (5 executive, 5 independent including 1 woman independent director)
  • CSR Spend: ₹50.92 million (against requirement of ₹35.84 million) across education, healthcare, rural development, and wildlife protection
  • CSR Implementation: Satish Wagh Foundation (CSR Registration No. CSR00015931)
  • Unspent CSR: ₹15.08 million transferred to separate account

Cash Flow and Financial Position

  • Net Cash from Operating Activities: ₹1,857.69 million
  • Net Cash used in Investing Activities: ₹(1,761.74) million primarily for fixed assets
  • Net Cash used in Financing Activities: ₹(98.82) million primarily for dividend payment
  • Property, Plant & Equipment: ₹6,833.17 million net
  • Capital Work-in-Progress: ₹355.48 million
  • Inventories: ₹1,595.97 million
  • Trade Receivables: ₹2,194.48 million

Forward-looking Statements

The document contains forward-looking statements subject to risks and uncertainties. The company undertakes no obligation to publicly update any forward-looking statements.